Co-delivery of human adipose-derived stromal cells and endothelial colony-forming cells in cell-assembled decellularized adipose tissue scaffolds for applications in soft tissue regeneration.
From SA., Walker JT., Gillis CJ., Ronald JA., Hess DA., Flynn LE.
Animal Study, published in Acta Biomater (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Acta Biomater (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41616887
- DOI
- 10.1016/j.actbio.2026.01.048
Abstract (original English)
Cellular therapies involving the co-delivery of cells with complementary pro-regenerative functionality hold promise as a strategy to promote soft tissue augmentation and regeneration. In particular, the co-delivery of adipose-derived stromal cells (ASCs) and endothelial colony-forming cells (ECFCs) has shown promise for regenerating stable blood vessels in vivo. The current study developed "cell-assembled" scaffolds for co-delivering human ASCs and ECFCs within a supportive decellularized adipose tissue (DAT) matrix, with the objective of enhancing their localized retention and augmenting their capacity to stimulate adipose tissue regeneration. Human ASCs and ECFCs were seeded separately onto human-derived DAT microcarriers under cell-type specific conditions. The cell-seeded microcarriers were then combined and cultured for 8 days under conditions that promoted matrix remodeling to fuse the microcarriers into 3D engineered tissues containing ASCs+ECFCs, ASCs alone, or ECFCs alone. Co-culture with ECFCs within the scaffolds was shown to modulate ASC pro-angiogenic gene expression, with some ECFCs forming tubule-like structures in vitro in both the ASC+ECFC and ECFC alone groups. In vivo bioluminescence imaging using a dual luciferase reporter system showed that co-delivery with ASCs enhanced ECFC retention following subcutaneous implantation in athymic nu/nu mice, but co-deliv
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.